Histopathological and molecular profiling of lung adenocarcinoma skin metastases reveals specific features.
EGFR
KRAS
PD-L1
TTF-1
skin metastases
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
20
07
2021
received:
14
01
2021
accepted:
25
07
2021
pubmed:
28
7
2021
medline:
1
3
2022
entrez:
27
7
2021
Statut:
ppublish
Résumé
Little is known regarding the histopathological and molecular features of lung adenocarcinoma skin metastases. Our study is the largest, to our knowledge, to comprehensively explore these to date. We performed a retrospective cohort study analysing 42 lung adenocarcinoma skin metastasis samples obtained from a database of 2659 lung adenocarcinomas collected between 2010 and 2020. EGFR exon 19 deletion was detected in one patient and KRAS mutations were detected in 12 (33.3%) patients. The programmed cell death ligand 1 (PD-L1) tumour proportion score was <1% in 27 patients, ≥1% and <50% in eight patients, ≥50% in six patients and not assessable in one patient. We showed that the predominant histopathological subtype is different from that at other metastatic sites (P = 0.024). Thyroid transcription factor I (TTF-1) was more often negative in skin metastases compared to other sites (P < 0.001). The EGFR mutation rate tended to be lower for skin metastases compared to other sites (P = 0.079). Skin metastases were associated with a high rate of PD-L1-negative cases (P = 0.022). Our work shows that the skin metastases of lung adenocarcinoma have a specific histopathological profile.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1051-1060Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 2018; 68; 394-424.
Walters S, Maringe C, Coleman MP et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax 2013; 68; 551-564.
Barlesi F, Mazieres J, Merlio JP et al. Routine molecular profileing of patients with advanced non-small-cel lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup. Lancet 2016; 387; 1415-1426.
Ferrara MG, Di Noia V, D’Argento E et al. Oncogene-addicted non-small-cell lung cancer: treatment opportunities and future perspectives. Cancers 2020; 12; 1196.
Shaukat I, Kern JJ, Höti N et al. Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics. Hum. Pathol. 2019; 84; 18-25.
Forest F, Stachowicz M-L, Casteillo F et al. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: value of testing on samples with poor specimen adequacy and analysis of discrepancies. Exp. Mol. Pathol. 2017; 103; 306-310.
Yu HA, Sima CS, Shen R et al. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J. Thorac. Oncol. 2015; 10; 431-437.
Wang H, Agulnik J, Kasymjanova G et al. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma. Lung Cancer 2019; 132; 36-38.
Miyagi J, Kinjo T, Tsuhako K et al. Extremely high Langerhans cell infiltration contributes to the favourable prognosis of HPV-infected squamous cell carcinoma and adenocarcinoma of the lung. Histopathology 2001; 38; 355-367.
Zilionis R, Engblom C, Pfirschke C et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 2019; 50; 1317-1334.e10.
Moreira AL, Ocampo PSS, Xia Y et al. A grading system for invasive pulmonary adenocarcinoma: a proposal from the International Association for the Study of Lung Cancer Pathology Committee. J. Thorac. Oncol. 2020; 15; 1599-1610.
Mansuet-Lupo A, Bobbio A, Blons H et al. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest 2014; 146; 633-643.
Casteillo F, Guy J-B, Dal-Col P et al. Pathologic subtypes of lung adenocarcinoma brain metastasis is a strong predictor of survival after resection. Am. J. Surg. Pathol. 2018; 42; 1701-1707.
Marcoval J, Penín RM, Llatjós R et al. Cutaneous metastasis from lung cancer: retrospective analysis of 30 patients. Australas. J. Dermatol. 2012; 53; 288-290.
Travis WD, Brambilla E, Nicholson AG et al. WHO Classification of tumours of the lung, pleura, thymus and heart. Lyon: IARC, 2015.
Rokutan-Kurata M, Yoshizawa A, Nakajima N et al. Discohesive growth pattern (Disco-p) as an unfavorable prognostic factor in lung adenocarcinoma: an analysis of 1062 Japanese patients with resected lung adenocarcinoma. Mod. Pathol. 2020; 33; 1722-1731.
Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma-an executive summary. Proc. Am. Thorac. Soc. 2011; 8; 381-385.
Da Cruz V, Yvorel V, Casteillo F et al. Histopathological subtyping is a prognostic factor in stage IV lung adenocarcinoma. Lung Cancer 2020; 147; 77-82.
Bourhis A, Remoué A, Le Flahec G et al. Avoiding non-contributive molecular results in cancer samples: proposal of a score-based approach for sample choice. Pathology 2019; 51; 524-528.
R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2018.
Therneau TA. Package for survival analysis in S. R package version 3.2-11; 2012. Available at: https://CRAN.R-project.org/package=survival
Alcaraz I, Cerroni L, Rütten A et al. Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review. Am. J. Dermatopathol. 2012; 34; 347-393.
Hu SCS, Chen GS, Wu CS et al. Rates of cutaneous metastases from different internal malignancies: experience from a Taiwanese medical center. J. Am. Acad. Dermatol. 2009; 60; 379-387.
Takahashi Y, Eguchi T, Lu S et al. Preponderance of high-grade histologic subtype in autologous metastases in lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 2018; 197; 816-818.
Pelosi G, Scarpa A, Forest F et al. The impact of immunohistochemistry on the classification of lung tumors. Exp. Rev. Respir. Med. 2016; 10; 1105-1121.
Casteillo F, Fournel P, Da Cruz V et al. TTF-1-positive metastatic endometrioid carcinoma. Appl. Immunohistochem. Mol. Morphol. 2017; 00; 1.
Schilsky JB, Ni A, Ahn L et al. Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. Lung Cancer 2017; 108; 205-211.
Zito Marino F, Rossi G, Montella M et al. Heterogeneity of PD-L1 expression in lung mixed adenocarcinomas and adenosquamous carcinomas. Am. J. Surg. Pathol. 2020; 44; 378-386.
Gagné A, Enlow W, Pigeon M-A et al. Comprehensive assessment of PD-L1 staining heterogeneity in pulmonary adenocarcinomas using tissue microarrays: impact of the architecture pattern and the number of cores. Am. J. Surg. Pathol. 2018; 42; 687-694.
Ng Kee Kwong F, Laggner U, McKinney O et al. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas. Histopathology 2018; 72; 1024-1032.
Forest F, Casteillo F, Da Cruz V et al. Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes. Lung Cancer 2021; 155; 1-9.
Kabashima K, Honda T, Ginhoux F et al. The immunological anatomy of the skin. Nat. Rev. Immunol. 2019; 19; 19-30.
Bulman A, Neagu M, Constantin C. Immunomics in skin cancer-improvement in diagnosis, prognosis and therapy monitoring. Curr. Proteomics 2013; 10; 202-217.
Schulman JM, Pauli ML, Neuhaus IM et al. The distribution of cutaneous metastases correlates with local immunologic milieu. J. Am. Acad. Dermatol. 2016; 74; 470-476.
Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 2016; 375; 1823-1833.
Gandhi L, Rodríguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 2018; 378; 2078-2292.
Frederickson AM, Arndorfer S, Zhang I et al. Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. Immunotherapy 2019; 11; 407-428.
Bai R, Lv Z, Xu D et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark. Res. 2020; 8; 34.
Hong L, Negrao MV, Dibaj SS et al. Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC. J. Thorac. Oncol. 2020; 15; 1449-1459.
Soria JC, Ohe Y, Vansteenkiste J et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 2018; 378; 113-125.
Jordan EJ, Kim HR, Arcila ME et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017; 7; 596-609.
Cadranel J, Mauguen A, Faller M et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-Part 2). J. Thorac. Oncol. 2012; 7; 1490-1502.